Cancer Causes & Control

, Volume 18, Issue 2, pp 211–218 | Cite as

Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer

  • Vincent L. Freeman
  • Robert C. Flanigan
  • Mohsen Meydani
Original Paper



Results from some observational studies suggest that diet and energy balance influence the clinical course of early-stage prostate cancer. To evaluate possible mechanisms, we prospectively examined the relation between prostatic concentrations of fatty acids at diagnosis and cancer recurrence following primary therapy.


Fatty acids were measured by capillary gas chromatography in fresh, non-cancerous prostate tissue collected from 184 men undergoing radical prostatectomy for clinically localized prostate cancer. Their association with risk of biochemical disease recurrence (a rising serum prostate-specific antigen following a disease-free [<0.1 ng/ml] interval ≥6 months) was analyzed using Cox proportional hazards models incorporating patient age, body mass index, tumor characteristics at diagnosis, and ethnicity.


During an average follow-up of 48.7 months (median = 47), 14 patients experienced biochemical recurrence. Percent total polyunsaturated fatty acid and the ratio of oleic-to-stearic acid associated with risk (multivariable hazards ratio [HR] = 0.51, 95% confidence interval [CI] = 0.29 to 0.90, p = 0.021 and HR = 1.68, 95% CI = 1.21 to 2.33, p = 0.002, respectively, per 1 standard deviation increase).


The results of this study are preliminary, but they suggest that pre-diagnostic prostatic concentrations of fatty acids associate with risk of biochemical recurrence following radical prostatectomy for clinically localized prostate cancer.


Prostatic neoplasms Diet and nutrition Body mass index Biochemical recurrence Prognosis 


  1. 1.
    Jemal A, Siegel R, Ward E et al (2006) Cancer statistics. CA Cancer J Clin 56:106–130PubMedCrossRefGoogle Scholar
  2. 2.
    Ries LAG, Eisner MP, Kosary CL et al (eds) SEER Cancer statistics review, 1975–2002, National Cancer Institute. Bethesda, MD, Table XXIIII-4. Based on November 2004 SEER data submission, posted to the SEER web site 2005. (Last accessed September 12, 2006)
  3. 3.
    National Comprehensive Cancer Network, Clinical Practice Guideline in Oncology: Prostate cancer. (v.2.2005, January 26, 2006). (Last accessed September 12, 2006)
  4. 4.
    Freedland SJ, Presti JC, Amling CL et al (2003) Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 61:736–741PubMedCrossRefGoogle Scholar
  5. 5.
    Ward JF, Moul JW (2005) Biochemical recurrence after definitive prostate cancer therapy. Part 1: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol 15:181–186PubMedCrossRefGoogle Scholar
  6. 6.
    Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766–771PubMedCrossRefGoogle Scholar
  7. 7.
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517–523PubMedCrossRefGoogle Scholar
  8. 8.
    Tewari A, Issa M, El-Galley R et al (2001) Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. Mol Urol 5:163–169PubMedCrossRefGoogle Scholar
  9. 9.
    Amling CL, Riffengurgh RH, Sun L et al (2004) Pathologic variables and recurrence rates as related to obesity in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22:439–445PubMedCrossRefGoogle Scholar
  10. 10.
    Freeland SJ, Aronson WJ, Kane CJ et al (2004) Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Region Cancer Hospital Database Study Group. J Clin Oncol 22:446–453CrossRefGoogle Scholar
  11. 11.
    Strom SS, Wang X, Pettaway CA et al (2005) Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11:6889–6894PubMedCrossRefGoogle Scholar
  12. 12.
    Chan JM, Holik CN, Leitzmann MF et al (2006) Diet after diagnosis and risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 17:199–208PubMedCrossRefGoogle Scholar
  13. 13.
    Calle EE, Kaaks R (2004) Overweight, obesity, and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579–591PubMedCrossRefGoogle Scholar
  14. 14.
    Campbell JK, Canene-Adams K, Lindshield BL et al (2004) Tomato phytochemicals and prostate cancer risk. J Nutr 134(12 Suppl):3486S–3492SPubMedGoogle Scholar
  15. 15.
    Chung BH, Mitchell SH, Zhang JS (2001) Effects of docosahexanoic acid and eicosapentaenoic acid on androgen-medicated cell growth in LNCaP prostate cancer cells. Carcinogenesis 22:1201–1206PubMedCrossRefGoogle Scholar
  16. 16.
    Freeman VL, Meydani M, Hur K, Flanigan RC (2004) Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate cancer. Cancer 101:2744–2754PubMedCrossRefGoogle Scholar
  17. 17.
    Hunter D (1998) Biochemical indicators of dietary intake. In: Willett W (ed) Nutritional Epidemiology, 2nd edn. Oxford University Press, New York, NY pp 174–243Google Scholar
  18. 18.
    Gleason DF (1977) Histologic grading of and staging of prostatic carcinoma. In: Tannenbaum M (ed) Urologic pathology: the prostate. Lea & Febiger, Philadelphia pp 171–197Google Scholar
  19. 19.
    Fleming ID, Cooper JS, Henson DE (1998) AJCC cancer staging manual, 5th edn. Lippincott-Raven, PhiladelphiaGoogle Scholar
  20. 20.
    Bova GS, Fox WM, Epstein IJ (1993) Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue, review of processing techniques. Mol Pathol 6:201–207Google Scholar
  21. 21.
    Caruso U, Fowler M, Erceg M, Romano C (1991) Determination of very long chain fatty acids in plasma by a simplified gas chromatographic-mass spectrometric procedure. J Chromatogr 562:147–152PubMedGoogle Scholar
  22. 22.
    Woodrum DL, French CM, Hill TM et al (1997) Analytical performance of the Tandem®-R free PSA immuno-assay measuring free prostate specific antigen. Clin Chem 43:1203–1208PubMedGoogle Scholar
  23. 23.
    Kalbfleisch JD, Prentice RL (1980) Statistical analysis of failure time data. Wiley, New York, NYGoogle Scholar
  24. 24.
    Therneau TM,Grambsch PM (2000) Modeling survival data. Extending the Cox Model. Springer, New York, NYGoogle Scholar
  25. 25.
    SAS [computer program] (2002–2003) Version 9.1. Cary, NC: SAS Institute, IncGoogle Scholar
  26. 26.
    Hussain T, Gupta S, Mukhtar H (2003) Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191:125–135PubMedCrossRefGoogle Scholar
  27. 27.
    Ghosh J, Myers CE. (1998) Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 95:13182–13187PubMedCrossRefGoogle Scholar
  28. 28.
    Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79:935–945PubMedGoogle Scholar
  29. 29.
    Collett GP, Betts AM, Johnson MI et al (2000) Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res 6:3241–3248PubMedGoogle Scholar
  30. 30.
    Eastwood M (2003) Principles of human nutrition, 2nd edn. Blackwell Science Ltd, Oxford, UKGoogle Scholar
  31. 31.
    Dobrzyn A, Ntambi JM (2004) The role of stearoyl-CoA desaturates in body weight regulation. Trends Cardiovasc Med 14:77–81PubMedCrossRefGoogle Scholar
  32. 32.
    Ntambi JM Miyazaki M, Stoehr PH et al (2002) Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. PNAS 99:11482–11486CrossRefGoogle Scholar
  33. 33.
    Okada T, Furuhashi N, Kuromori Y, Miyashita M, Iwata F, Harada K (2005) Plasma palmitoleic acid content and obesity in children. Am J Clin Nutr 82:747–750PubMedGoogle Scholar
  34. 34.
    Baillargeon J, Rose DP (2006) Obesity, adipokines, and prostate cancer (review). Int J Oncol 28:737–745PubMedGoogle Scholar
  35. 35.
    Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115:911–999PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Vincent L. Freeman
    • 1
    • 2
    • 3
  • Robert C. Flanigan
    • 3
  • Mohsen Meydani
    • 4
  1. 1.Division of Epidemiology and Biostatistics, School of Public HealthUniversity of Illinois at ChicagoChicagoUSA
  2. 2.Center for Population Health and Health DisparitiesUniversity of Illinois at ChicagoChicagoUSA
  3. 3.Department of UrologyLoyola University Stritch School of MedicineMaywoodUSA
  4. 4.Vascular Biology Laboratory, Jean Mayer USDA Human Nutrition Research Center on AgingTufts UniversityBostonUSA

Personalised recommendations